Solid Tumor Therapeutics Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 191.58 Billion |
| Market Size (2029) | USD 283.83 Billion |
| CAGR (2024 - 2029) | 8.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Solid Tumor Therapeutics Market Analysis
The Solid Tumor Therapeutics Market size is estimated at USD 191.58 billion in 2024, and is expected to reach USD 283.83 billion by 2029, growing at a CAGR of 8.20% during the forecast period (2024-2029).
The factors driving the growth of the solid tumor therapeutics market include the increasing incidence of cancer, surging research and development activities in solid tumor therapeutics, and rising drug approvals. In addition, increasing government initiatives for cancer awareness are also expected to drive market growth during the forecast period. The high burden of cancer is expected to boost the demand for solid tumor therapeutics for cancer treatment, propelling the market’s growth. For instance, according to the European Breast Cancer Coalition's report published in October 2023, one in 11 women in the European Union were diagnosed with breast cancer before the age of 74.
According to January 2024 statistics published by Breast Cancer Now, about 55,000 women are diagnosed with breast cancer in the United Kingdom every year. The same source reported that 46,000 people are diagnosed with breast cancer in England every year, followed by 4,700 in Scotland, 2,800 in Wales, and 1,500 in Northern Ireland. Thus, the high burden of breast cancer worldwide is expected to accelerate the demand for solid tumor therapeutics for breast cancer, thereby boosting the market’s growth during the forecast period.
In addition, rising strategic initiatives by market players to launch advanced solid tumor therapeutics augment the market growth. For instance, in August 2023, Impilo Therapeutics, Inc. launched to enable nucleic acid-based medicines to treat solid tumor cancers effectively. The company signed an agreement with Lisata Therapeutics, Inc. for the targeted delivery of nucleic acid-based drugs for solid tumor cancer indications.
Therefore, owing to the factors above, such as the high burden of cancer, rising clinical trial developments, and increasing product launches, the market studied is anticipated to grow during the forecast period. However, stringent regulatory reforms and price erosion due to generic competition are expected to restrain the growth of this market.
Solid Tumor Therapeutics Market Trends
Breast Cancer is Expected to Witness Growth During the Forecast Period
The breast cancer segment is expected to register healthy growth during the forecast period owing to the high burden of breast cancer and rising product launches by market players. The high burden of breast cancer globally is expected to boost the demand for advanced solid tumor therapeutics, accelerating market growth. For instance, as per the Canadian Medical Association Journal report published in May 2022, around 28.6 thousand new breast cancer cases were diagnosed in Canada in 2022, which accounted for 25% of the total new cancers diagnosed in women in Canada in the same year.
According to the Australian Institute of Health and Welfare (AIHW) 2022 report, around 20.6 thousand new breast cancer cases were diagnosed in Australia in 2022. Moreover, according to an article published in the National Center of Biotechnology Information in February 2022, 429.1 thousand breast cancer cases were diagnosed in Chinese women in 2022.
Initiatives by the government to educate people about early breast cancer diagnosis and treatment further add to the market’s growth. For instance, in May 2022, the US Department of Health and Human Services (HHS) awarded funding worth USD 5 million to community health centers to increase equitable access to life-saving cancer screenings. Such initiatives are projected to increase the diagnosis, thereby propelling the use of solid tumor breast cancer therapeutics during the forecast period.
Furthermore, market players' rising research studies and strategic initiatives are expected to significantly contribute to the segment's growth during the forecast period. For instance, in February 2023, Gilead Sciences Inc. received the US Food and Drug Administration’s (FDA) approval for Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The drug has been proven to treat solid tumors in clinical trials.
Therefore, owing to the high burden of breast cancer and strategic initiatives by market players, the segment is expected to hold a significant market share during the forecast period.
North America is Expected to Hold Significant Market Share Over the Forecast Period
North America is expected to hold a significant share of the market studied owing to the high burden of cancer cases, research and development spending, and the strong presence of market players.
The high burden of solid tumors, such as breast, lung, and colorectal cancers, drives market growth. For instance, according to the American Cancer Society 2023 statistics, around 1.9 million new cancer cases were estimated to be diagnosed in the United States in 2023, out of which an estimated 153 thousand colorectal cancer and 238.3 thousand lung and bronchus cancer were estimated to be diagnosed in the same year. Therefore, the high burden of new cancer cases is projected to boost R&D in developing advanced solid tumor therapeutics, accelerating regional market growth.
According to an article updated in March 2023 by the National Institute of Health, the grants provided by the US government for the research and development of ovarian, colorectal, and lung cancers were USD 178 million, USD 346 million, and USD 479 million, respectively, in 2022. Such high spending is projected to develop advanced solid tumor therapeutics for these cancers, thereby fueling market growth in the region.
Therefore, the high burden of solid tumors, along with the high spending on cancer research and development, increases the demand for treatment products, which is expected to boost market growth in the region during the forecast period.
Solid Tumor Therapeutics Industry Overview
The solid tumor therapeutics market, driven by a growing demand for cancer treatments and the rising prevalence of the disease, is witnessing moderate competition. While a handful of major players currently hold significant market shares, the landscape is poised for the entry of smaller players, who are anticipated to carve out their own substantial market presence. Notable players in this market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, GSK PLC, and Eli Lilly and Company.
These companies invest heavily in research and development to introduce innovative therapies and improve treatment options. Additionally, strategic collaborations, mergers, and acquisitions are common strategies these key players employ to strengthen their market position. The market is also influenced by regulatory approvals and the availability of advanced diagnostic tools, which facilitate early detection and treatment of solid tumors.
Solid Tumor Therapeutics Market Leaders
-
Amgen Inc.
-
AstraZeneca PLC
-
Hoffmann-La Roche AG
-
Eli Lilly and Company
-
GSK plc
*Disclaimer: Major Players sorted in no particular order
Solid Tumor Therapeutics Market News
- April 2024: Aubex Therapeutics Inc., a biotechnology firm, was launched with a motive to battle cancer. The company's initial program is focused on novel compounds aimed at transforming the treatment of solid tumor malignancies through a unique approach to modifying the tumor microenvironment (TME).
- February 2024: Iovance Biotherapeutics Inc. received the US FDA’s approval for its Amtagvi or lifileucel, the first T-cell immunotherapy drug for a solid tumor. The FDA granted Amtagvi an accelerated approval for patients with advanced melanoma following prior treatment with a PD-1 inhibitor and a BRAF inhibitor if the tumor carries a BRAF V600 mutation.
Solid Tumor Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumption and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Incidence of Cancer
- 4.2.2 Rising Research and Development Activities and Product Launches and Approvals
- 4.2.3 Increasing Government Initiatives for Cancer Awareness
-
4.3 Market Restraints
- 4.3.1 Stringent Regulatory Reforms
- 4.3.2 Price Erosion due to Generic Competition
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Cancer Type
- 5.1.1 Breast Cancer
- 5.1.2 Lung Cancer
- 5.1.3 Colorectal Cancer
- 5.1.4 Prostate Cancer
- 5.1.5 Cervical Cancer
- 5.1.6 Other Cancer Types
-
5.2 By Drug Type
- 5.2.1 Carboplatin
- 5.2.2 Cisplatin
- 5.2.3 Gemcitabine
- 5.2.4 Paclitaxel
- 5.2.5 Doxorubicin
- 5.2.6 Bevacizumab
- 5.2.7 Erlotinib
- 5.2.8 Sunitinib
- 5.2.9 Everolimusa
- 5.2.10 Other Drug Types
-
5.3 By Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories Inc.
- 6.1.2 Amgen Inc.
- 6.1.3 AstraZeneca PLC
- 6.1.4 Baxter International Inc.
- 6.1.5 Biogen Inc.
- 6.1.6 Boehringer Ingelheim GmbH
- 6.1.7 Bristol-Myers Squibb Company
- 6.1.8 Eli Lilly and Company
- 6.1.9 F. Hoffmann-La Roche AG
- 6.1.10 GSK PLC
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablitySolid Tumor Therapeutics Industry Segmentation
As per the report's scope, solid tumor therapeutics are pharmaceuticals that specifically treat various cancers, such as breast, lung, colorectal, prostate, and cervical cancer. Solid tumors are abnormal tissue masses that usually do not contain cysts or liquid areas.
The solid tumor therapeutics market is segmented by cancer type, drug type, and geography. By cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other cancer types. By drug type, the market is segmented into carboplatin, cisplatin, gemcitabine, paclitaxel, doxorubicin, bevacizumab, erlotinib, sunitinib, everolimusa, and other drug types. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for the above segments.
| By Cancer Type | Breast Cancer | |
| Lung Cancer | ||
| Colorectal Cancer | ||
| Prostate Cancer | ||
| Cervical Cancer | ||
| Other Cancer Types | ||
| By Drug Type | Carboplatin | |
| Cisplatin | ||
| Gemcitabine | ||
| Paclitaxel | ||
| Doxorubicin | ||
| Bevacizumab | ||
| Erlotinib | ||
| Sunitinib | ||
| Everolimusa | ||
| Other Drug Types | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Solid Tumor Therapeutics Market Research FAQs
How big is the Solid Tumor Therapeutics Market?
The Solid Tumor Therapeutics Market size is expected to reach USD 191.58 billion in 2024 and grow at a CAGR of 8.20% to reach USD 283.83 billion by 2029.
What is the current Solid Tumor Therapeutics Market size?
In 2024, the Solid Tumor Therapeutics Market size is expected to reach USD 191.58 billion.
Who are the key players in Solid Tumor Therapeutics Market?
Amgen Inc., AstraZeneca PLC, Hoffmann-La Roche AG, Eli Lilly and Company and GSK plc are the major companies operating in the Solid Tumor Therapeutics Market.
Which is the fastest growing region in Solid Tumor Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Solid Tumor Therapeutics Market?
In 2024, the North America accounts for the largest market share in Solid Tumor Therapeutics Market.
What years does this Solid Tumor Therapeutics Market cover, and what was the market size in 2023?
In 2023, the Solid Tumor Therapeutics Market size was estimated at USD 175.87 billion. The report covers the Solid Tumor Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Solid Tumor Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Solid Tumor Therapeutics Industry Report
Statistics for the 2024 Solid Tumor Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Solid Tumor Therapeutics analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
